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Background/Aims: Cross-sectional studies have documented that 2-10% of patients who are chronically infected with hepatitis 
C virus (HCV) are also positive for hepatitis B virus (HBV) surface antigen (HBsAg). Data related to HCV-HBV coinfection are 
lacking in Korea. This study evaluated the clinical characteristics, the treatment efficacy of peginterferon alfa plus ribavirin, and 
the changes induced by such treatment in HBV status in chronic hepatitis C (CHC) patients coinfected with HBV. Methods: Eighteen 
(2.37%) HBsAg-positive CHC patients were selected from among the 758 subjects from the K(G)yeonggi-Incheon Peginterferon 
alfa and ribavirin in chronic hepatitis C Treatment (KIPECT) study, which evaluated the treatment efficacy and safety of 
peginterferon alfa plus ribavirin in CHC patients. Data on changes in the status of HBV infections were obtained. Results: HCV 
genotype 1b was the most common (44%). The overall sustained virologic response rate was 72% in all patients, and 60% and 
87.5% in genotypes 1 and 2, respectively. Two of the 18 patients were positive for HBeAg, and 15 had baseline HBV DNA level 
of less than 2,000 IU/mL. Two of the three whose levels exceeded this threshold showed no detectable DNA after treatment. 
After the completion of treatment, serum HBV DNA levels were increased in the two patients whose baseline HBV DNA levels 
were less than 2,000 IU/mL. Conclusions: The prevalence of HBV coinfection in CHC patients was 2.37% and most of the 
patients were inactive carriers. The treatment efficacy was similar to that of HCV mono-infection. Reactivation of HBV replication 
was observed in some patients after CHC treatment. (Korean J Hepatol 2011;17:199-205)
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INTRODUCTION
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection 
are the major causes of chronic liver disease worldwide and 
can lead to cirrhosis and hepatocellular carcinoma (HCC).
1,2 
Coinfection of these two hepatotropic virus is reported not to be 
rare. Studies from outside Korea reported that approximately 
5-7% of HBV-infected patients also were positive for anti-HCV
 
and 2-10% of chronic hepatitis C (CHC) patients were positive 
for hepatitis B surface antigen (HBsAg).
3,4 In non-endemic areas, 
HBV and HCV coinfection is predominantly found in several 
high risk populations, such as intravenous drug users, patients on 
hemodialysis, recipients of organ transplantations, and human 
immunodeficiency virus positive patients.
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areas including Korea, the frequency of HBV infection provides 
the basis for an appreciable rate of HBV and HCV coinfection in 
the general population.
3
Some cross-sectional studies reported that in comparison with 
monoinfection, HBV and HCV coinfection was associated with 
higher prevalence of liver cirrhosis and hepatic decom-
pensation.
5-7 Several studies also revealed that HBV and HCV 
coinfection increased the risk of developing HCC.
8-10 With 
respect to the treatment response, there was a report suggesting 
that HBV coinfected CHC patients responded poorly to the 
treatment.
11
There has been no research on coinfection of HBV and HCV 
in Korea, except for a report of 0.1% of anti-HCV seropositivity 
in HBsAg positive subjects in 2005.
12 Therefore, no sufficient 
recommendation for the patients with HBV and HCV coinfection 
was provided by the current guideline.
13
This retrospective, multicenter study aimed to investigate the 
prevalence of HBV and HCV coinfection in Korea, clinical and 
virologic characteristics, treatment efficacy of peginterferon and 
ribavirin combination therapy, and the change in the status of 
HBV infection following the treatment of CHC patients.
PATIENTS AND METHODS
Patients
HBsAg positive subjects were selected from the K(G)yeonggi- 
Incheon Peginterferon alfa and ribavirin Effect in Chronic 
hepatitis C Treatment (KIPECT) study which evaluated the 
treatment efficacy and safety of peginterferon plus ribavirin 
therapy in 758 CHC patients.
14 A total of 18 HBsAg positive 
patients among the 758 subjects were retrospectively included 
from eight university hospitals. In KIPECT study, CHC patients 
with detectable serum HCV RNA and/or elevated serum alanine 
aminotransferase levels for more than 6 months, age ≥18 years, 
and treated with peginterferon alfa plus ribavirin from January 
2000 to September 2008 were included. Exclusion criteria were 
acute hepatitis C patients, history of prior exposure to interferon 
or peginterferon, and no available data on genotype of HCV. The 
study protocol was approved by the Institutional Review Board 
of each hospital and was conducted in accordance with the 
principles of the Declaration of Helsinki.
Treatment of chronic hepatitis C 
The study patients were treated with either pegylated interferon 
alfa-2a plus ribavirin or pegylated interferon alfa-2b plus ribavirin. 
Initial dosage and dose modification of the treatment drug was 
determined based on the current guideline suggested by the 
Korean Association for the Study of the Liver.
15 Duration of the 
treatment was planned as 24 weeks for genotype 2/3 infection 
and 48 weeks for non genotype 2/3 infection.
15 
Data collection
Baseline clinical and virologic characteristics were obtained 
by retrospective review of medical records, and when available, 
histologic data before the treatment were also recorded. HCV 
RNA values measured in copies/mL were converted into IU/mL 
using conversion factor according to the used assay in each 
hospital.
2 Serum HCV RNA levels were determined using the 
COBAS TaqMan HCV test (Roche Molecular System Inc., 
Branchburg, NJ, USA) in five institutes, Cobas Amplicor HCV 
Monitor V2.0 (Roche Molecular System Inc., Branchburg, NJ, 
USA), Abbott RealTime (Abott Diagnostics, Abbott Park, 
Illinois, USA), and Artus HCV RG RT-PCR Kit (Qiagen, 
Valencia, CA, USA) in one institute, respectively. Pre-and 
post-treatment hepatitis B e antigen (HBeAg), anti-hepatitis e 
antibody, HBV DNA values, and history of other treatment 
modalities used for HBV infection were recorded. Baseline 
histologic data concerning steatosis and fibrosis were collected. 
Hepatic steatosis was assessed as either presence or none, and 
the degree of hepatic fibrosis was classified as recommended by 
Korean Study Group for the Pathology of Digestive Disease: 
grade 0, no fibrosis; grade 1, portal fibrosis; grade 2, periportal 
fibrosis; grade 3, septal fibrosis; grade 4, cirrhosis.
16 Data 
collection was performed using an case record form in the charge 
of doctors in the individual hospital from April 2009 to 
December 2009. 
Definition and evaluation of the treatment 
response of CHC
The early virologic response (EVR), end of treatment response 
(ETR) and sustained virologic response (SVR) were used to 
investigate the treatment response of CHC proposed by The 
Korean association for the study of the liver.
15 Quantitative HCV 
RNA values were recorded which were determined at baseline, at 
12 week after the treatment, and at the time of the treatment 
termination for HCV of genotype 1. Based on the level of HCV 
RNA value at 12 week, the presence of EVR was judged as either 
complete (HCV RNA negative) or partial (reduction in HCV Yu Jin Kim, et al. Treatment of HBV and HCV coinfection  201
Table 1. Baseline demographics and clinical characteristics 
Factor
Age, years 44.1±9.5
Male/Female, n 12/6
Intravenous drug user, n (%) 1 (5.6)
History of a transfusion, n (%) 1 (5.6)
ALT, IU/mL 72.0±36.3
Prothrombin time, INR 1.0±0.1
Albumin, g/dL 4.2±0.4
Platelet, ×10
3/mm
3 182.3±81.6
Fibrosis  ≥ Grade 2, n (%) 5 (27.8)
Steatosis, n (%)  0 (0)
Pegylated interferon alfa 2a/2b, n 10/8
Data represent mean±SD or number (%). 
ALT, alanine aminotransferase.
Table 2. Baseline data of HBV infection in the CHC patients
Factor n (%)
  HBeAg(-), HBV DNA < 2,000 IU/mL 14 (77.7)
  HBeAg(-), HBV DNA ≥ 2,000 IU/mL 2 (11.1)
  HBeAg(+), HBV DNA < 2,000 IU/mL  1 (5.6)
  HBeAg(+), HBV DNA ≥ 2,000 IU/mL 1 (5.6)
HBV, hepatitis B virus; CHC, chronic hepatitis C; HBeAg, 
hepatitis B virus e antigen; SD, standard deviation.
RNA level more than 2 log compared to baseline HCV RNA 
level). For CHC patients infected with genotype 2/3 HCV, 
quantitative HCV RNA levels of baseline and at the time of 
treatment termination were recorded. Regardless of genotype, 
ETR was defined as HCV RNA negativity at the end of 
treatment. SVR was defined as HCV RNA negativity measured 
at 24 weeks after cessation of treatment in all genotype.
Statistical analysis
The mean±standard deviation (SD) was used to describe 
continuous variables and categorical variables were presented as 
the number with a percent. Comparison of continuous variables 
was performed with a student’s t-test and Fisher’s exact test was 
used to compare categorical variables. P-values less than 0.05 
were considered to be statistically significant. All data were 
analyzed using SPSS (version 15.0; Chicago, IL, USA). 
RESULTS
Demographics and baseline characteristics
Eighteen out of 758 CHC patients in the KIPECT study were 
positive for HBsAg. The prevalence of HBV-HCV coinfection 
was 2.37%. The mean age of the subjects was 44.1 years and 
males constituted 66% of the total. When categorized by the age 
in detail, 1 patient (5.6%) was younger than 30 years, 5 patients 
(27.8%) were between 30 and 40 years, 8 patients (44.4%) were 
between 40 and 50 years, and 4 patients (22.2%) were older than 
50 years. One patient had a history of intravenous drug use and 
another patient had a history of transfusion. None were 
coinfected with human immunodeficiency virus. Histologic data 
was available in 5 patients and all had fibrosis of stage 2 and 
no steatosis. There was no patient with clinical or histologic 
evidences of liver cirrhosis. Other detailed baseline characteristics 
of the study subjects are presented in Table 1.
Baseline status of coinfection with HBV and HCV 
Genotype 1b was found in eight patients (44%) and was the 
most common HCV genotype. Genotype 2a/c was present in 5 
(28%) and was the second most common. Genotype 2 unclassified 
and 1a was seen in 3 (17%) and 2 (11%) patients, respectively. 
Mean value of baseline HCV RNA was 8.79×10
6±1.45×10
7 
IU/mL and 11 patients (61.1%) had HCV RNA level more than 
600,000 IU/mL. Sixteen of the 18 patients (88.8%) were negative 
for HBeAg and 15 (83.3%) patients had HBV DNA level less 
than 2,000 IU/mL. Other data concerning HBV infection are 
detailed in Table 2. Serum HCV RNA levels were compared 
between patients with and without detectable serum HBV 
DNA. HCV RNA level was 4.9×10
6±6.7×10
6 IU/mL in patients 
with detectable HBV DNA and 1.6×10
7±2.1×10
7 IU/mL in 
patients without detectable DNA, although there was no statistical 
significance (P=0.257). HCV RNA levels were also compared 
according to HBeAg status. It was 2.4×10
7±2.7×10
7 IU/mL in 
HBeAg positive patients and 5.7×10
7±8.4×10
7 IU/mL in 
HBeAg negative patients (P=0.367). The proportion of CHC 
patients with high viral load (HCV RNA > 600,000 IU/mL) was 
not significantly different according to detectable serum HBV 
DNA (P=1.000) and HBeAg status (P=1.000).
Treatment efficacy of peginterferon alfa plus 
ribavirin in chronic hepatitis C
Overall, fourteen out of the 18 patients (77.8%) showed EVR 
and 16 patients (88.9%) had ETR. Thirteen patients showed SVR 
(72.2%) regardless of the genotype. Treatment responses 
according to HCV genotype are presented in Figure 1. The SVR 202  The Korean Journal of Hepatology Vol. 17. No. 3, September 2011
%
Figure 1. Treatment responses according to HCV genotype. In 
genotype 1 (n=10), the rates of EVR (early virologic response), 
ETR (end of treatment response), and SVR (sustained virologic 
response) were 80%, 80%, and 60%, respectively; the corresponding 
rates in genotype 2 (n=8), were 75%, 100%, and 87.5%.
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Figure 3. Clinical courses of the patients who developed flare-up of CHB after CHC treatment. (A) Serum HBV DNA level was 
increased after treatment of HCV infection in a 44-year-old man without breakthrough hepatitis. (B) The serum HBV DNA level 
was increased in a 38-year-old man after treatment with accompanying flare-up hepatitis.
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Figure 2. Changes in HBV DNA level after CHC treatment. Two 
of the 13 patients whose baseline HBV DNA was < 2,000 IU/mL 
developed viral replication after HCV treatment (marked as
*), 
while the HBV DNA levels of the other patients remained stable. 
Two of the three patients with baseline HBV DNA levels >2,000 
IU/mL had no detectable HBV DNA at the end of treatment.
rate was 60% in genotype 1 and 87.5% in genotype 2 (Fig. 1). 
Changes in hepatitis B virus after treatment of 
chronic hepatitis C
Peginterferon alfa is also approved for the treatment of CHB.
13 
In this study, no one developed seroclearance or seroconversion 
of HBsAg or HBeAg after the completion of treatment. Post- 
treatment HBV DNA values were available in 16 patients. The 
change of serum HBV DNA levels before and after treatment of 
CHC is presented in Figure 2. Three patients had a baseline HBV 
DNA value exceeding 2,000 IU/mL and HBV DNA was 
undetectable in 2 of these 3 patients after the treatment. Two of 
the 3 patients with a baseline HBV DNA level under 2,000 
IU/mL exhibited increase of HBV DNA level more than 1 log 
from the baseline. A 44-year-old male patient with genotype 1b 
infection had undetectable baseline HBV DNA (limit of 
detection 12 IU/mL) and was negative for HBeAg before 
treatment of CHC. Serum HCV RNA level was 9,340,000 IU/mL 
at baseline. He achieved ETR and subsequently showed SVR 
after the treatment with peginterferon plus ribavirin for 48 
weeks, however, serum HBV DNA was increased to 4,444 
IU/mL. Biochemical breakthrough or reversion of HBeAg was 
not observed and no additional therapy for HBV infection 
was administered. The clinical course of another patient who 
developed flare-up of CHB is presented in detail (Fig. 3A). A 
38-year-old man infected with HCV genotype 1b additionally 
received entecavir for HBV infection after treatment of CHC. 
Baseline HBeAg was positive and serum HBV DNA was 1,552 
A B
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IU/mL. After the 48 week treatment of peginterferon plus ribavirin, 
serum aspartate aminotransferase and alanine aminotransferase 
levels were elevated with achievement of the ETR. When other 
potential etiologies of acute hepatitis were surveyed, it was 
absent. Serum HBV DNA level increased to 153,844,063 IU/mL 
and 0.5 mg/day of entecavir was prescribed to manage 
flare-up of CHB. HCV RNA was positive at 24 weeks after the 
treatment and SVR was not observed in this patient (Fig. 3B). 
DISCUSSION
HBV and HCV share many risk factors for infection, thus 
coinfection with both viruses is not uncommon.
3 However, 
the worldwide prevalence of coinfection with HBV and HCV 
is unknown due to lack of large-scale population-based studies.
4 
Furthermore, since is scant information on the treatment of HBV 
and HCV coinfection, the current guidelines cannot suggest 
specific approved treatment for this patient group.
1,13
Data from outside of Korea reported that 2-10% of CHC 
patients are also HBsAg positive.
4 In areas where HBV infection 
is endemic, like in Korea, a substantial number of patients 
are infected with both viruses.
17-19 Even though Korea is a 
representative endemic area of HBV infection, there has hitherto 
been no systemic study about HBV and HCV coinfection. A 
study that surveyed serologic markers of various viral hepatitis 
and reviewed the prevalence of concurrent infection reported 
that seven of 5131 HBsAg positive subjects (approximately 
0.1%) were also positive for anti-HCV in 2005.
12 To date, this 
was the only study that investigated HBV and HCV coinfection 
in Korea. This study was hampered by the lack of detailed 
clinical or virologic information. It is remarkable that this current 
study is the first report of HBV and HCV coinfection in the 
Korean population and the prevalence of HBV coinfection in 
CHC patients was 2.37%. 
Certain high risk patients, such as intravenous drug users, 
patients on hemodialysis, patients with human immunodeficiency 
virus infection, and recipients of organ transplants are frequently 
coinfected with HBV and HCV.
4 In areas of high prevalence of 
HBV infection, HCV superinfection in individuals with CHB is 
the most common scenario of HBV and HCV coinfection.
20 In 
this study, only one CHC patient had a history of intravenous 
drug use, which may reflect some difference in the epidemiology 
between other countries. However, due to the retrospective 
nature of this study, there is a possibility of underestimation of 
such risk factors for coinfection.
Dual or triple hepatitis virus infections are associated with 
viral interference.
18 Clinical and laboratory studies have shown 
that HBV and HCV interact with each other and that generally 
HCV exerts a suppressive effect on HBV.
4,18 This has been 
corroborated by reports that described the occurrence of HBeAg 
seroconversion and HBsAg seroclearance in HCV superinfected 
CHB patients.
20,21 In our study, 88% of the study subjects were 
negative for HBeAg, and 83% had HBV DNA <2,000 IU/mL, 
which provides additional evidence for the suppression of HBV 
replication by HCV. Although no statistical significances were 
observed, HCV RNA was measured to be higher in HBeAg 
positive patients than that of negative patients. HCV RNA was 
also higher and in patients without detectable serum HBV DNA. 
These finding can be another evidence of suppressive effect of 
HCV on HBV. While the inhibitory effect of HCV was observed 
only in genotype 1 HCV infection in one study,
4 it was 
impossible to prove this association in our study because of the 
small number of patients. 
Combination of peginterferon alfa and ribavirin is now 
recommended as the standard treatment for chronic HCV 
monoinfection.
2 Since very limited data regarding therapy of 
HBV and HCV coinfected patients are available, there are 
currently no established treatment guidelines for these patients.
4 
Although one small study reported that neither peginterferon nor 
conventional interferon based regimens were effective for HBV 
coinfected CHC,
11 a recent large randomized prospective 
trial from Taiwan showed that the combination therapy with 
peginterferon plus ribavirin was equally effective in patients 
with HCV monoinfection and in those with HBV and HCV 
coinfection.
22 Another study from China concluded that, when 
compared with HCV monoinfected patients, the SVR rate was 
similar, but relapse rate of patients with HCV genotype 1 
infection in the coinfection group was high.
23 In our study, the 
overall SVR rate regardless of HCV genotype was 72.2%, and 
patients with HCV genotype 1 and 2 showed a SVR rate of 60% 
and 87.5%, respectively. When considering the reported treatment 
outcomes in Korea, an overall SVR rate of 59.6-82.8%, SVR rate 
of 53.6% to 69.6% in genotype 1 and genotype 4, and SVR rate 
of 71.4 % to 90.2% in genotype 2 and 3,
14,24-27 it seems to be 
indicative of similar treatment response rates in HBV coinfected 
CHC patients compared to patients with HCV monoinfection. 
Previous studies have indicated that successful clearance of 
HCV may lead to reactivation of HBV in approximately one- 
third of patients.
22-24 In this study, HBV DNA levels were 
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whose baseline HBV DNA was <2,000 IU/mL. Although increase 
of HBV DNA did not result in flare-up hepatitis in one patient, 
biochemical breakthrough occurred in another patient and 
antiviral therapy against HBV was subsequently administered to 
manage CHB. So, while treating HBV coinfected CHC patients, 
the possibility of HBV reactivation should be considered even in 
the inactive carrier of HBV, and HBV DNA level should be 
carefully followed up. 
Several studies have compared the histologic findings 
between HBV and HCV coinfection with HCV monoinfection, 
and concluded that liver injury or fibrosis are more severe in 
coinfection.
6,22,28 In this study, data on histology was available 
in only 5 patients and none of them had advanced fibrosis. 
Unfortunately, due to the small number of sample size, the 
severity of fibrosis in HBV and HCV coinfected patients could 
not be evaluated in this study. There have also been several 
case-control studies showing an increased risk of developing 
HCC in coinfected patients.
5-8 A meta-analysis conducted to 
evaluate the impact of HBV and HCV coinfection on the 
development of HCC demonstrated the significantly higher 
relative risk of HCC in coinfected patients (odds ratio=165) than 
HBV (odds ratio=22.5) or HCV (odds ratio=17.3) monoinfection.
29 
In general, patients with HCC or decompensated cirrhosis are not 
considered as a candidate for interferon based therapy. Because 
this study only included CHC patients treated with peginterferon 
plus ribavirin, there is a possibility that most of the patients with 
history of HCC or advanced cirrhosis might have been excluded. 
Therefore, evaluation about development of HCC or advanced 
cirrhosis in HBV and HCV coinfected patients is considered to 
be impossible in this study subjects and it is an area of further 
research. 
This study has some limitations. First, the prevalence rate of 
HBV and HCV coinfection of 2.37% was much lower than 
reported data of 2-10%,
4 and there is a possibility of underes-
timation. We only included candidates of HCV treatment, 
patients with detectable HCV RNA in blood. Moreover, the 
proportion of CHC patients who do not require treatment due to 
various reasons are not considered in this study. Secondly, 
possible occult HBV infection was not considered. Occult HBV 
infection has frequently been identified in patients with HCV 
infection, and the prevalence has been recorded as high as 
48.9%.
30,31 The retrospective design involving a relatively small 
number of subjects is acknowledged drawback. Because the 
present study had a short follow-up period, the long-term 
consequence of coinfection including the development of cirrhosis 
or HCC could not be evaluated. Further prospective research for 
long-term prognosis of HBV and HCV coinfection is required. 
Nevertheless, it is meaningful in that this is the first study to 
survey HBV and HCV coinfection in Korea, and paves the way 
for more comprehensive studies. Further large, multicenter, 
prospective studies are necessary to investigate accurate epide-
miology, viral characteristics, and long term prognosis of HBV 
and HCV coinfection regarding the development of viral relapse, 
cirrhosis, and HCC. It also will be helpful to Korean guideline by 
collecting data from Korean population. Also, more studies are 
necessary to determine the optimal treatment regimen, especially 
to prevent HBV reactivation or elucidate the possible additional 
role of potent oral nucleotide/nucleoside analogues in HBV and 
HCV coinfected patients.
In summary, the prevalence of HBV coinfection in CHC 
patients was 2.37%, most of the coinfected patients had low 
levels of HBV DNA, and were inactive carriers. Treatment 
efficacy of peginterferon alfa and ribavirin combination for the 
coinfected patients was quite similar to patients with HCV 
monoinfection. After treatment of CHC and viral suppression 
of HCV, some patients were prone to reactivation of HBV 
replication.
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